{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:50:59Z","timestamp":1777679459484,"version":"3.51.4"},"reference-count":14,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.25-0634","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:08:50Z","timestamp":1775686130000},"page":"n\/a","source":"Crossref","is-referenced-by-count":1,"title":["Hyperprogression after Anti-Programmed Death-1 Therapy in a Case of Sigmoid Colon Cancer with Lynch Syndrome"],"prefix":"10.70352","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1532-9124","authenticated-orcid":false,"given":"Ryota","family":"Miura","sequence":"first","affiliation":[{"name":"Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7246-5390","authenticated-orcid":false,"given":"Gaku","family":"Ohira","sequence":"additional","affiliation":[{"name":"Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-3975","authenticated-orcid":false,"given":"Toru","family":"Tochigi","sequence":"additional","affiliation":[{"name":"Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-3882","authenticated-orcid":false,"given":"Koichiro","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5931-7596","authenticated-orcid":false,"given":"Atsushi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2335-4704","authenticated-orcid":false,"given":"Hisahiro","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17\u201348.","DOI":"10.3322\/caac.21763"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919\u201332.","DOI":"10.1056\/NEJMra012242"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines. J Clin Oncol 2015; 33: 209\u201317.","DOI":"10.1200\/JCO.2014.58.1322"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383: 2207\u201318.","DOI":"10.1056\/NEJMoa2017699"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409\u201313.","DOI":"10.1126\/science.aan6733"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018; 4: 1543\u201352.","DOI":"10.1001\/jamaoncol.2018.3676"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Wolchok JD, Hoos A, O\u2019Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412\u201320.","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin Cancer Res 2017; 23: 1920\u20138.","DOI":"10.1158\/1078-0432.CCR-16-1741"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 2017; 23: 4242\u201350.","DOI":"10.1158\/1078-0432.CCR-16-3133"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Park HJ, Kim KW, Pyo J, et al. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology 2020; 297: 87\u201396.","DOI":"10.1148\/radiol.2020200443"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Jia W, Gao Q, Han A, et al. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med 2019; 16: 655\u201370.","DOI":"10.20892\/j.issn.2095-3941.2019.0144"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Lo Russo G, Moro M, Sommariva M, et al. Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade. Clin Cancer Res 2019; 25: 989\u201399.","DOI":"10.1158\/1078-0432.CCR-18-1390"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Lee JH, Long GV, Menzies AM, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol 2018; 4: 717\u201321.","DOI":"10.1001\/jamaoncol.2017.5332"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med 2018; 24: 1441\u20138.","DOI":"10.1038\/s41591-018-0134-3"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0634\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T04:06:46Z","timestamp":1775880406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0634\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0634","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.25-0634"}}